Camurus develops innovative and long-acting drugs for the treatment of serious and chronic diseases, such as opioid dependence, pain, cancer and endocrine disorders, based on its proprietary formulation technology FluidCrystal®. The Camurus share (CAMX) has been listed on Nasdaq Stockholm’s Mid Cap segment since 2015.
